Keno joined BGV as a Partner in 2021. He serves on the supervisory board of Dualyx, Fibrocor and two BGV companies in stealth. Prior to joining BGV, Keno was a Vice President at M Ventures responsible for Biotech investments (Biopharma and Life Sciences). While at M Ventures he served as Board Member or Observer to the board of several biotech companies including Xilio, Immunitas, Soteria, DNA Script, Riffyn, Inthera, Galecto, iOnctura, ApoGen and iOmx.

Keno has over 20 years of Biotech experience spanning investing (private and public equities at M Ventures and Omega Funds), investment banking (Piper Sandler), management consulting (IQVIA), and medical research (MRC).

Keno is a Fellow of the Royal Society of Medicine, holds a PhD in Genetics from University College in London and an MBA from INSEAD. His research in lipid metabolism has been published in the top scientific journal Nature.